Bioyetin 4000 IU contains Erythropoietin (EPO), a hormone that helps the bone marrow produce red blood cells. It is prescribed for the management of anemia, especially in patients with chronic kidney disease, those undergoing dialysis, or individuals receiving chemotherapy. By increasing red blood cell count, it helps relieve common symptoms of anemia such as tiredness, weakness, and reduced stamina.
Composition
-
Erythropoietin (Recombinant Human EPO) 4000 IU
Dosage Form
-
Injection (pre-filled syringe or vial)
Uses
-
Anemia associated with chronic kidney disease (with or without dialysis)
-
Anemia related to chemotherapy treatment
-
Pre-surgical patients, to reduce the need for blood transfusion
How to Use
-
Administered either subcutaneously (under the skin) or intravenously (into a vein).
-
Dose and schedule depend on hemoglobin levels, patient condition, and response to treatment.
-
Should only be given by a qualified healthcare professional.
-
Regular blood tests are required to monitor progress and adjust the dose if needed.
Expert Advice
-
Do not self-inject unless properly trained by a doctor.
-
Report immediately if you notice chest pain, swelling in legs, shortness of breath, or severe headache (may signal blood clot risk).
-
Blood pressure should be monitored regularly during therapy.
-
Your doctor may prescribe iron supplements to improve treatment response.
-
Store in a refrigerator (2–8°C). Do not freeze. Protect from light and keep out of reach of children.
Possible Side Effects
-
Increased blood pressure
-
Headache or dizziness
-
Muscle or joint pain
-
Redness or swelling at injection site
-
Rare but serious: blood clots, seizures, or pure red cell aplasia (PRCA)
Reviewed by:
Dr. Kamran Javed
Consultant Hematologist · Specialist in Anemia & Blood Disorders
Important
This information is provided for awareness only. Bioyetin 4000 IU should be used strictly under medical supervision. Do not adjust your dose, self-inject, or stop treatment without your doctor’s guidance.
Reviews
There are no reviews yet.